Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
, 65 (5), 623-633

Guidelines for the Preanalytical Conditions for Analyzing Circulating Cell-Free DNA

Affiliations

Guidelines for the Preanalytical Conditions for Analyzing Circulating Cell-Free DNA

Romain Meddeb et al. Clin Chem.

Abstract

Circulating cell-free DNA (cfDNA) isolated from blood has been identified as a potential biomarker in numerous fields, and has been the object of intensive research over the past decade, although its original discovery dates back 60 years. While it is already used routinely in commercial and clinical practice in oncology and prenatal testing, other potential applications have emerged, including for diabetes, cardiovascular diseases, organ transplantation, autoimmune diseases, sepsis, trauma, and sport management. As with the discovery and development of any biomarker, preanalytical requirements and documentation are as important as analytical requirements. Except for the case of noninvasive prenatal testing and prenatal diagnosis, the implementation of cfDNA in a clinical setting remains limited because of the lack of standardization of cfDNA analysis. In particular, only a few attempts have been made to collect and pool scientific data on the relevant preanalytical factors, and no standard operating procedure has yet been set. For this report, we have performed a thorough and systematic search via MEDLINE® for relevant preanalytical variables and patient factors. These form the basis of the guidelines we propose for analyzing nuclear cfDNA.

Similar articles

See all similar articles

Cited by 7 PubMed Central articles

See all "Cited by" articles

Publication types

LinkOut - more resources

Feedback